In the growing field of personalized medicine, scientists at Yale University have found promising evidence that a simple ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

After breaking his hand and injuring his shoulder last year, Brian sought out much-needed medical attention, which led to him learning that he had cancer.

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

"Lung cancer ranks third in terms of new cases but second in terms of mortality in Vietnam. Of the over 24,000 new cases ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...